Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10227238" target="_blank" >RIV/00179906:_____/14:10227238 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/14:43875252

Výsledek na webu

<a href="http://dx.doi.org/10.2174/9781608058228114060003" target="_blank" >http://dx.doi.org/10.2174/9781608058228114060003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/9781608058228114060003" target="_blank" >10.2174/9781608058228114060003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives

Popis výsledku v původním jazyce

Alzheimer's disease (AD) is a multifactorial disorder and apparently involves several different etiopathogenetic mechanisms. Up-to-date, there are no curative treatments or effective disease modifying therapies for AD. A strategy to enhance the cholinergic transmission by using acetylcholinesterase inhibitors (AChEIs) has been proposed more than two decades ago. Food and Drug Administration (FDA) gradually marketed these AChEIs: tacrine (1993), donepezil (1997), rivastigmine (2000) and galantamine (2001); tacrine is no longer used because of its high prevalence of hepatotoxicity. In addition to the AD cholinergic hypothesis , there is great evidence that voltage-gated, uncompetitive, N-methyl-D-aspartate (NMDA) antagonist memantine with moderate affinity can protect neurons from excitotoxicity. It was approved by FDA for treatment of moderate to severe stages of AD in 2003. Beyond symptomatic approaches there are anti-amyloid, neuroprotective and neuron-restorative strategies that hold

Název v anglickém jazyce

Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives

Popis výsledku anglicky

Alzheimer's disease (AD) is a multifactorial disorder and apparently involves several different etiopathogenetic mechanisms. Up-to-date, there are no curative treatments or effective disease modifying therapies for AD. A strategy to enhance the cholinergic transmission by using acetylcholinesterase inhibitors (AChEIs) has been proposed more than two decades ago. Food and Drug Administration (FDA) gradually marketed these AChEIs: tacrine (1993), donepezil (1997), rivastigmine (2000) and galantamine (2001); tacrine is no longer used because of its high prevalence of hepatotoxicity. In addition to the AD cholinergic hypothesis , there is great evidence that voltage-gated, uncompetitive, N-methyl-D-aspartate (NMDA) antagonist memantine with moderate affinity can protect neurons from excitotoxicity. It was approved by FDA for treatment of moderate to severe stages of AD in 2003. Beyond symptomatic approaches there are anti-amyloid, neuroprotective and neuron-restorative strategies that hold

Druh

C - Kapitola v odborné knize

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

O - Projekt operacniho programu

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Frontiers in Drug Design &amp; Discovery. Volume 6

ISBN

978-1-60805-822-8

Počet stran výsledku

37

Strana od-do

702-738

Počet stran knihy

766

Název nakladatele

Bentham Science

Místo vydání

Neuveden

Kód UT WoS kapitoly

—